Shedding Light on Tardive Dyskinesia: A Video Discussion With Michael Asbach

In a recent interview, hosted by Matthew Shapiro and Haley Amering, they welcomed Dr. Michael Asbach to discuss tardive dyskinesia (TD) to shed light on this often misunderstood drug-induced movement disorder. Dr. Asbach emphasized that TD is not limited to individuals with severe mental illnesses like schizophrenia; it can also impact people on various medications for different conditions. Shapiro stresses the importance of awareness, urging individuals to discuss any abnormal movements with their healthcare provider. Ultimately, the video aims to raise awareness about TD during TD Awareness Week, highlighting the significance of recognizing symptoms and seeking appropriate medical guidance.

Study Reveals Comorbidities and Outcomes in Psychiatric Inpatients With Tardive Dyskinesia: Implications for Severe Illness and Healthcare Costs

Researchers of a study analyzed comorbidities and outcomes in psychiatric inpatients with tardive dyskinesia (TD). The study used a case-control design with data from the Nationwide Inpatient Sample, involving 77,022 adult inpatient admissions for mood disorders and schizophrenia. TD was found to be more common in older adults (50-64 years) and occurred in similar proportions among men and women. Patients with TD had a higher likelihood of cardio-metabolic comorbidities, including obesity, hypertension, and diabetes, compared with those without TD.

The researchers concluded that psychiatric inpatients with TD tend to have more severe illness, with those having schizophrenia and bipolar disorders being at the highest risk, and the presence of TD is associated with poorer hospital outcomes, including longer stays and higher costs for acute inpatient care.

Pregnant Woman Develops Nystagmus from Metoclopramide Hydrochloride: A Cautionary Tale for Healthcare Providers

Researchers of a report reviewed the case of a 15-week pregnant woman who developed drug-induced nystagmus, involuntary eye movement, after being prescribed metoclopramide hydrochloride, a medication frequently used for gastrointestinal issues such as nausea and vomiting. After several tests, it was determined that the metoclopramide hydrochloride was the probable cause of the nystagmus. Upon discontinuation, her symptoms disappeared.

Study Finds Patients With Tardive Dyskinesia Report Greater Impact on Quality of Life Than Healthcare Providers

A study presented at the International Association of Parkinsonism and Related Disorders World Congress found that patients with tardive dyskinesia (TD) perceive a greater impact on their quality of life compared with healthcare providers. The respondents rated the extent of TD’s impact across psychological/emotional, physical, professional, and social domains using a 10-point Likert scale.

The results showed that patients and providers both reported the psychological/emotional domain as the most impacted by TD. Patients also reported a greater impact on the physical domain compared with providers. In terms of the professional domain, patients reported a significantly higher impact across all eight subdomains, particularly in interactions at work/school and the ability to perform tasks independently. Overall, patients reported a greater impact of TD across all domains vs providers.

Awareness of Abnormal Movements in Tardive Dyskinesia Linked to Adverse Effects on Physical and Social Well-Being, Study Shows

Researchers of a recent study found that adults who were aware of abnormal involuntary movements indicative of tardive dyskinesia (TD) experienced adverse effects on physical wellness and social functioning. Participants were divided into two cohorts: Cohort 1 consisted of patients with no visible abnormal movements, and Cohort 2 included individuals with possible TD according to clinician judgment. Cohort 2 was further divided into those aware of their movements in the past 4 weeks (cohort 2A) and those unaware of their movements during that time (cohort 2NA).

The results showed that individuals in cohorts 2 and 2A reported more problems in various dimensions of health and social functioning compared to those in modified cohort 1. The study highlights the importance of considering patient perceptions and awareness of their own abnormal movements and the impact of TD on their overall wellness.

Study Finds Patient Perception of Tardive Dyskinesia’s Impact Differs From Clinician Assessment

Researchers of a study examined the impact of tardive dyskinesia (TD) patient health and social functioning, conducted in two cohorts: Cohort 1 consisted of patients with no abnormal involuntary movements, while Cohort 2 consisted of patients with possible TD according to clinicians’ judgment. The assessments included measuring health utility using EuroQoL’s EQ-5D-5L, social functioning using the Sheehan Disability Scale (SDS), as well as patient- and clinician-rated severity and impact of TD.
The results showed that in Cohort 2, patient-rated TD impact was significantly associated with lower health utility and higher SDS scores. However, clinician-rated severity was moderately associated with both health utility and SDS, but these associations were not statistically significant. The study concluded that the severity of TD assessed by clinicians did not always correlate with patient perceptions of the significance of TD.

Case Study Highlights Tardive Dystonia in Patient With Alzheimer’s on Antipsychotics: Implications for Treatment and Management

Researchers of a recent study looked at a case of tardive dystonia in a 61-year-old woman with Alzheimer’s dementia, who had been taking antipsychotic medication and presented with a sustained flexion posture of the neck that made feeding difficult. Treatment of tardive dystonia can be challenging, and the first step usually involves discontinuing the neuroleptic medication, if possible. However, this may not be feasible for psychiatric patients, in which case, switching to a different antipsychotic, such as clozapine, is recommended. If there is no improvement, other drugs like VMAT2 inhibitors, anticholinergic drugs, clonazepam, and baclofen can be tried. Researchers concluded that preference should be given to antipsychotics with a lower risk of extrapyramidal effects, such as clozapine, in patients with dementia.